Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG GENES KEGG PATHWAY KEGG DRUG DrugBank Disease ID
1 SIGMAR1 [2] Amyotrophic lateral sclerosis, Pathways of neurodegeneration - multiple diseases D00848 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
2 SIGMAR1 [2] Amyotrophic lateral sclerosis, Pathways of neurodegeneration - multiple diseases D03742 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
3 SIGMAR1 [2] Amyotrophic lateral sclerosis, Pathways of neurodegeneration - multiple diseases D03744 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
4 TUBB3 [10] Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D00570 Colchicine [7] 2, 42, 46, 56, 93, 210, 266
5 TUBB4A [10] Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D00570 Colchicine [7] 2, 42, 46, 56, 93, 210, 266
6 TUBB4B [10] Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D00570 Colchicine [7] 2, 42, 46, 56, 93, 210, 266
7 CYSLTR1 [2] Calcium signaling pathway, Neuroactive ligand-receptor interaction D01385 Ibudilast [2] 2, 13
8 CHRM1 [8] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D00113 Atropine [2] 2, 299
9 CHRM1 [8] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D00138 Scopolamine [1] 2
10 CHRM1 [8] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D01077 Atropine [2] 2, 299
11 CHRM1 [8] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D02069 Atropine [2] 2, 299
12 CHRM1 [8] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D03011 Atropine [2] 2, 299
13 CHRM1 [8] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D03814 Atropine [2] 2, 299
14 CHRM2 [6] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton D00113 Atropine [2] 2, 299
15 CHRM2 [6] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton D00138 Scopolamine [1] 2
16 CHRM2 [6] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton D01077 Atropine [2] 2, 299
17 CHRM2 [6] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton D02069 Atropine [2] 2, 299
18 CHRM2 [6] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton D03011 Atropine [2] 2, 299
19 CHRM2 [6] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton D03814 Atropine [2] 2, 299
20 CHRM3 [11] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D00113 Atropine [2] 2, 299
21 CHRM3 [11] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D00138 Scopolamine [1] 2
22 CHRM3 [11] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D01077 Atropine [2] 2, 299
23 CHRM3 [11] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D02069 Atropine [2] 2, 299
24 CHRM3 [11] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D03011 Atropine [2] 2, 299
25 CHRM3 [11] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D03814 Atropine [2] 2, 299
26 CHRM4 [3] Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton D00113 Atropine [2] 2, 299
27 CHRM4 [3] Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton D00138 Scopolamine [1] 2
28 CHRM4 [3] Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton D01077 Atropine [2] 2, 299
29 CHRM4 [3] Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton D02069 Atropine [2] 2, 299
30 CHRM4 [3] Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton D03011 Atropine [2] 2, 299
31 CHRM4 [3] Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton D03814 Atropine [2] 2, 299
32 CHRM5 [6] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D00113 Atropine [2] 2, 299
33 CHRM5 [6] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D00138 Scopolamine [1] 2
34 CHRM5 [6] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D01077 Atropine [2] 2, 299
35 CHRM5 [6] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D02069 Atropine [2] 2, 299
36 CHRM5 [6] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D03011 Atropine [2] 2, 299
37 CHRM5 [6] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D03814 Atropine [2] 2, 299
38 CNR1 [4] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Retrograde endocannabinoid signaling D00306 Dronabinol [8] 2, 8, 13, 36, 46, 96, 271, 298
39 CNR1 [4] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Retrograde endocannabinoid signaling D10915 Cannabidiol [19] 2, 6, 8, 13, 36, 46, 95, 96, 97, 140, 144, 145, 156, 157, 158, 193, 206, 226, 271
40 CNR2 [1] Neuroactive ligand-receptor interaction D00306 Dronabinol [8] 2, 8, 13, 36, 46, 96, 271, 298
41 CNR2 [1] Neuroactive ligand-receptor interaction D10915 Cannabidiol [19] 2, 6, 8, 13, 36, 46, 95, 96, 97, 140, 144, 145, 156, 157, 158, 193, 206, 226, 271
42 ADORA1 [7] cGMP-PKG signaling pathway, cAMP signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D00528 Caffeine [9] 2, 6, 13, 21, 46, 78, 96, 97, 265
43 ADORA1 [7] cGMP-PKG signaling pathway, cAMP signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D01453 Caffeine [9] 2, 6, 13, 21, 46, 78, 96, 97, 265
44 ADORA2A [7] Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease, Alcoholism D00528 Caffeine [9] 2, 6, 13, 21, 46, 78, 96, 97, 265
45 ADORA2A [7] Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease, Alcoholism D01453 Caffeine [9] 2, 6, 13, 21, 46, 78, 96, 97, 265
46 CSF3R [5] Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer D03235 Filgrastim [34] 2, 6, 11, 13, 16, 25, 26, 28, 34, 35, 36, 38, 40, 41, 42, 45, 46, 47, 49, 51, 57, 60, 62, 65, 85, 96, 113, 164, 256, 283, 284, 285, 296, 331
47 CSF3R [5] Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer D03247 Lenograstim [7] 2, 13, 16, 18, 19, 57, 65
48 ADRA1D [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D00454 Olanzapine [2] 2, 8
49 ADRA1D [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D06623 Olanzapine [2] 2, 8
50 ADRA1B [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D00454 Olanzapine [2] 2, 8
51 ADRA1B [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D06623 Olanzapine [2] 2, 8
52 ADRA1A [7] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D00454 Olanzapine [2] 2, 8
53 ADRA1A [7] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D06623 Olanzapine [2] 2, 8
54 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00514 Dexmedetomidine [13] 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280
55 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00560 Pimozide [1] 2
56 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D01205 Dexmedetomidine [13] 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280
57 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D04375 Guanabenz [2] 2, 13
58 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00514 Dexmedetomidine [13] 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280
59 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D01205 Dexmedetomidine [13] 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280
60 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D04375 Guanabenz [2] 2, 13
61 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00514 Dexmedetomidine [13] 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280
62 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D01205 Dexmedetomidine [13] 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280
63 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D04375 Guanabenz [2] 2, 13
64 ADRB2 [9] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D07713 Clenbuterol [5] 1, 2, 6, 13, 256
65 DDC [9] Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Cocaine addiction, Amphetamine addiction, Alcoholism D00558 Carbidopa [9] 2, 4, 6, 13, 17, 90, 140, 164, 201
66 DRD1 [10] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Morphine addiction, Alcoholism D00059 Levodopa [8] 2, 4, 6, 17, 90, 140, 164, 201
67 DRD1 [10] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Morphine addiction, Alcoholism D09886 Dexpramipexole [1] 2
68 DRD2 [8] Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D00059 Levodopa [8] 2, 4, 6, 17, 90, 140, 164, 201
69 DRD2 [8] Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D00454 Olanzapine [2] 2, 8
70 DRD2 [8] Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D00559 Pramipexole [3] 2, 6, 20
71 DRD2 [8] Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D00560 Pimozide [1] 2
72 DRD2 [8] Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D00784 Ropinirole [4] 2, 6, 74, 309
73 DRD2 [8] Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D01226 Sulpiride [5] 2, 6, 17, 46, 70
74 DRD2 [8] Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D05575 Pramipexole [3] 2, 6, 20
75 DRD2 [8] Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D06623 Olanzapine [2] 2, 8
76 DRD2 [8] Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D08489 Ropinirole [4] 2, 6, 74, 309
77 DRD2 [8] Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D08549 Sulpiride [5] 2, 6, 17, 46, 70
78 DRD2 [8] Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D09886 Dexpramipexole [1] 2
79 DRD2 [8] Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D09953 Pridopidine [3] 2, 6, 8
80 DRD3 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D00059 Levodopa [8] 2, 4, 6, 17, 90, 140, 164, 201
81 DRD3 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D00454 Olanzapine [2] 2, 8
82 DRD3 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D00559 Pramipexole [3] 2, 6, 20
83 DRD3 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D00784 Ropinirole [4] 2, 6, 74, 309
84 DRD3 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D05575 Pramipexole [3] 2, 6, 20
85 DRD3 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D06623 Olanzapine [2] 2, 8
86 DRD3 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D08489 Ropinirole [4] 2, 6, 74, 309
87 DRD3 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D09886 Dexpramipexole [1] 2
88 DRD4 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D00059 Levodopa [8] 2, 4, 6, 17, 90, 140, 164, 201
89 DRD4 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D00454 Olanzapine [2] 2, 8
90 DRD4 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D00559 Pramipexole [3] 2, 6, 20
91 DRD4 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D00784 Ropinirole [4] 2, 6, 74, 309
92 DRD4 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D05575 Pramipexole [3] 2, 6, 20
93 DRD4 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D06623 Olanzapine [2] 2, 8
94 DRD4 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D08489 Ropinirole [4] 2, 6, 74, 309
95 DRD4 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D09886 Dexpramipexole [1] 2
96 DRD5 [4] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Dopaminergic synapse D00059 Levodopa [8] 2, 4, 6, 17, 90, 140, 164, 201
97 DRD5 [4] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Dopaminergic synapse D09886 Dexpramipexole [1] 2
98 ABAT [7] Alanine, aspartate and glutamate metabolism, Valine, leucine and isoleucine degradation, beta-Alanine metabolism, Propanoate metabolism, Butanoate metabolism, Metabolic pathways, GABAergic synapse D00399 Valproic acid [17] 2, 3, 5, 6, 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331
99 TUBB [10] Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D00570 Colchicine [7] 2, 42, 46, 56, 93, 210, 266
100 EPOR [5] Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer D03231 Erythropoietin [10] 2, 6, 13, 18, 22, 46, 47, 70, 95, 96
101 ESR1 [9] Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D00966 Tamoxifen [4] 2, 86, 113, 227
102 ESR1 [9] Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D08559 Tamoxifen [4] 2, 86, 113, 227
103 ESR2 [7] Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D00966 Tamoxifen [4] 2, 86, 113, 227
104 ESR2 [7] Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D08559 Tamoxifen [4] 2, 86, 113, 227
105 MTOR [51] EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, HIF-1 signaling pathway, Phospholipase D signaling pathway, Autophagy - other, Autophagy - animal, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Cellular senescence, Apelin signaling pathway, Neutrophil extracellular trap formation, JAK-STAT signaling pathway, Th17 cell differentiation, Thermogenesis, Insulin signaling pathway, Thyroid hormone signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Growth hormone synthesis, secretion and action, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Shigellosis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Colorectal cancer, Pancreatic cancer, Glioma, Prostate cancer, Acute myeloid leukemia, Breast cancer, Hepatocellular carcinoma, Gastric cancer, Central carbon metabolism in cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Diabetic cardiomyopathy D00753 Sirolimus [41] 2, 6, 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331
106 GABBR1 [7] cAMP signaling pathway, Neuroactive ligand-receptor interaction, GABAergic synapse, Taste transduction, Estrogen signaling pathway, GnRH secretion, Morphine addiction D00241 Baclofen [7] 2, 10, 13, 18, 65, 149, 206
107 GABRA1 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
108 GABRA1 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00696 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
109 GABRA1 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D05028 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
110 GABRA2 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
111 GABRA2 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00696 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
112 GABRA2 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D05028 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
113 GABRA3 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
114 GABRA3 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00696 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
115 GABRA3 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D05028 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
116 GABRA4 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
117 GABRA4 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00696 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
118 GABRA4 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D05028 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
119 GABRA5 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
120 GABRA5 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00696 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
121 GABRA5 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D05028 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
122 GABRA6 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
123 GABRA6 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00696 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
124 GABRA6 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D05028 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
125 GABRB1 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
126 GABRB1 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00696 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
127 GABRB1 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D05028 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
128 GABRB2 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
129 GABRB2 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00696 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
130 GABRB2 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D05028 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
131 GABRB3 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
132 GABRB3 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00696 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
133 GABRB3 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D05028 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
134 GABRD [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
135 GABRD [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00696 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
136 GABRD [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D05028 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
137 GABRE [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
138 GABRE [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00696 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
139 GABRE [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D05028 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
140 GABRG1 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
141 GABRG1 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00696 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
142 GABRG1 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D05028 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
143 GABRG2 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
144 GABRG2 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00696 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
145 GABRG2 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D05028 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
146 GABRG3 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
147 GABRG3 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00696 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
148 GABRG3 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D05028 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
149 GABRP [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
150 GABRP [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00696 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
151 GABRP [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D05028 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
152 GAD1 [7] Alanine, aspartate and glutamate metabolism, beta-Alanine metabolism, Taurine and hypotaurine metabolism, Butanoate metabolism, Metabolic pathways, GABAergic synapse, Type I diabetes mellitus D00399 Valproic acid [17] 2, 3, 5, 6, 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331
153 GAD2 [7] Alanine, aspartate and glutamate metabolism, beta-Alanine metabolism, Taurine and hypotaurine metabolism, Butanoate metabolism, Metabolic pathways, GABAergic synapse, Type I diabetes mellitus D00399 Valproic acid [17] 2, 3, 5, 6, 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331
154 ABL1 [11] ErbB signaling pathway, Ras signaling pathway, Cell cycle, Axon guidance, Neurotrophin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, MicroRNAs in cancer, Chemical carcinogenesis - reactive oxygen species, Chronic myeloid leukemia, Viral myocarditis D03252 Bosutinib [2] 2, 67
155 GHR [5] Cytokine-cytokine receptor interaction, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Growth hormone synthesis, secretion and action D02691 Somatotropin [23] 2, 3, 13, 19, 46, 65, 74, 75, 76, 78, 96, 107, 113, 187, 191, 193, 195, 236, 238, 265, 274, 276, 299
156 GNRHR [2] Neuroactive ligand-receptor interaction, GnRH signaling pathway D00989 Leuprolide [5] 1, 2, 3, 51, 76
157 GRIA1 [14] cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Nicotine addiction D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
158 GRIA1 [14] cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Nicotine addiction D02696 Talampanel [2] 2, 6
159 GRIA1 [14] cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Nicotine addiction D08964 Perampanel [3] 2, 6, 144
160 GRIA2 [15] cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
161 GRIA2 [15] cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction D02696 Talampanel [2] 2, 6
162 GRIA2 [15] cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction D08964 Perampanel [3] 2, 6, 144
163 GRIA3 [13] cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Nicotine addiction, Transcriptional misregulation in cancer D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
164 GRIA3 [13] cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Nicotine addiction, Transcriptional misregulation in cancer D02696 Talampanel [2] 2, 6
165 GRIA3 [13] cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Nicotine addiction, Transcriptional misregulation in cancer D08964 Perampanel [3] 2, 6, 144
166 GRIA4 [10] cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Nicotine addiction D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
167 GRIA4 [10] cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Nicotine addiction D02696 Talampanel [2] 2, 6
168 GRIA4 [10] cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Nicotine addiction D08964 Perampanel [3] 2, 6, 144
169 GRIK1 [2] Neuroactive ligand-receptor interaction, Glutamatergic synapse D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
170 GRIK2 [2] Neuroactive ligand-receptor interaction, Glutamatergic synapse D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
171 GRIK3 [2] Neuroactive ligand-receptor interaction, Glutamatergic synapse D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
172 GRIK4 [2] Neuroactive ligand-receptor interaction, Glutamatergic synapse D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
173 GRIK5 [2] Neuroactive ligand-receptor interaction, Glutamatergic synapse D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
174 GRIN1 [18] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D00711 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
175 GRIN1 [18] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
176 GRIN1 [18] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D00848 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
177 GRIN1 [18] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D03742 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
178 GRIN1 [18] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D03744 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
179 GRIN1 [18] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D04905 Memantine [7] 2, 6, 8, 13, 49, 127, 205
180 GRIN1 [18] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D07283 Esketamine [3] 2, 4, 70
181 GRIN1 [18] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D08098 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
182 GRIN1 [18] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D08174 Memantine [7] 2, 6, 8, 13, 49, 127, 205
183 GRIN2A [19] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D00711 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
184 GRIN2A [19] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
185 GRIN2A [19] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D00848 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
186 GRIN2A [19] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D03742 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
187 GRIN2A [19] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D03744 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
188 GRIN2A [19] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D04905 Memantine [7] 2, 6, 8, 13, 49, 127, 205
189 GRIN2A [19] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D07283 Esketamine [3] 2, 4, 70
190 GRIN2A [19] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D08098 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
191 GRIN2A [19] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D08174 Memantine [7] 2, 6, 8, 13, 49, 127, 205
192 GRIN2B [19] Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D00711 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
193 GRIN2B [19] Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
194 GRIN2B [19] Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D00848 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
195 GRIN2B [19] Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D03742 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
196 GRIN2B [19] Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D03744 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
197 GRIN2B [19] Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D04905 Memantine [7] 2, 6, 8, 13, 49, 127, 205
198 GRIN2B [19] Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D07283 Esketamine [3] 2, 4, 70
199 GRIN2B [19] Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D08098 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
200 GRIN2B [19] Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D08174 Memantine [7] 2, 6, 8, 13, 49, 127, 205
201 GRIN2C [15] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D00711 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
202 GRIN2C [15] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
203 GRIN2C [15] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D00848 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
204 GRIN2C [15] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D03742 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
205 GRIN2C [15] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D03744 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
206 GRIN2C [15] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D04905 Memantine [7] 2, 6, 8, 13, 49, 127, 205
207 GRIN2C [15] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D07283 Esketamine [3] 2, 4, 70
208 GRIN2C [15] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D08098 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
209 GRIN2C [15] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D08174 Memantine [7] 2, 6, 8, 13, 49, 127, 205
210 GRIN2D [15] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D00711 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
211 GRIN2D [15] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
212 GRIN2D [15] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D00848 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
213 GRIN2D [15] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D03742 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
214 GRIN2D [15] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D03744 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
215 GRIN2D [15] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D04905 Memantine [7] 2, 6, 8, 13, 49, 127, 205
216 GRIN2D [15] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D07283 Esketamine [3] 2, 4, 70
217 GRIN2D [15] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D08098 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
218 GRIN2D [15] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D08174 Memantine [7] 2, 6, 8, 13, 49, 127, 205
219 NR3C1 [1] Neuroactive ligand-receptor interaction D00244 Betamethasone [7] 2, 28, 46, 83, 90, 96, 235
220 NR3C1 [1] Neuroactive ligand-receptor interaction D00407 Methylprednisolone [48] 2, 6, 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300
221 NR3C1 [1] Neuroactive ligand-receptor interaction D00473 Prednisone [48] 2, 6, 11, 13, 14, 19, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 79, 81, 84, 85, 86, 95, 96, 97, 113, 127, 162, 164, 205, 222, 224, 228, 251, 283, 284, 285, 288, 299, 300, 331
222 NR3C1 [1] Neuroactive ligand-receptor interaction D00751 Methylprednisolone [48] 2, 6, 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300
223 NR3C1 [1] Neuroactive ligand-receptor interaction D00972 Betamethasone [7] 2, 28, 46, 83, 90, 96, 235
224 NR3C1 [1] Neuroactive ligand-receptor interaction D00979 Methylprednisolone [48] 2, 6, 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300
225 NR3C1 [1] Neuroactive ligand-receptor interaction D01357 Betamethasone [7] 2, 28, 46, 83, 90, 96, 235
226 NR3C1 [1] Neuroactive ligand-receptor interaction D01402 Betamethasone [7] 2, 28, 46, 83, 90, 96, 235
227 NR3C1 [1] Neuroactive ligand-receptor interaction D01637 Betamethasone [7] 2, 28, 46, 83, 90, 96, 235
228 NR3C1 [1] Neuroactive ligand-receptor interaction D02032 Betamethasone [7] 2, 28, 46, 83, 90, 96, 235
229 NR3C1 [1] Neuroactive ligand-receptor interaction D02286 Betamethasone [7] 2, 28, 46, 83, 90, 96, 235
230 NR3C1 [1] Neuroactive ligand-receptor interaction D05000 Methylprednisolone [48] 2, 6, 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300
231 NR3C1 [1] Neuroactive ligand-receptor interaction D05001 Methylprednisolone [48] 2, 6, 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300
232 NR3C1 [1] Neuroactive ligand-receptor interaction D05002 Methylprednisolone [48] 2, 6, 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300
233 HLA-A [19] Endocytosis, Phagosome, Cellular senescence, Cell adhesion molecules, Antigen processing and presentation, Natural killer cell mediated cytotoxicity, Type I diabetes mellitus, Human cytomegalovirus infection, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Viral carcinogenesis, Autoimmune thyroid disease, Allograft rejection, Graft-versus-host disease, Viral myocarditis D04318 Glatiramer [4] 2, 13, 96, 156
234 HLA-B [19] Endocytosis, Phagosome, Cellular senescence, Cell adhesion molecules, Antigen processing and presentation, Natural killer cell mediated cytotoxicity, Type I diabetes mellitus, Human cytomegalovirus infection, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Viral carcinogenesis, Autoimmune thyroid disease, Allograft rejection, Graft-versus-host disease, Viral myocarditis D04318 Glatiramer [4] 2, 13, 96, 156
235 HLA-C [19] Endocytosis, Phagosome, Cellular senescence, Cell adhesion molecules, Antigen processing and presentation, Natural killer cell mediated cytotoxicity, Type I diabetes mellitus, Human cytomegalovirus infection, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Viral carcinogenesis, Autoimmune thyroid disease, Allograft rejection, Graft-versus-host disease, Viral myocarditis D04318 Glatiramer [4] 2, 13, 96, 156
236 HLA-DMA [24] Phagosome, Cell adhesion molecules, Antigen processing and presentation, Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, Intestinal immune network for IgA production, Type I diabetes mellitus, Leishmaniasis, Toxoplasmosis, Staphylococcus aureus infection, Tuberculosis, Influenza A, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Asthma, Autoimmune thyroid disease, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Viral myocarditis D04318 Glatiramer [4] 2, 13, 96, 156
237 HLA-DMB [24] Phagosome, Cell adhesion molecules, Antigen processing and presentation, Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, Intestinal immune network for IgA production, Type I diabetes mellitus, Leishmaniasis, Toxoplasmosis, Staphylococcus aureus infection, Tuberculosis, Influenza A, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Asthma, Autoimmune thyroid disease, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Viral myocarditis D04318 Glatiramer [4] 2, 13, 96, 156
238 HLA-DOA [24] Phagosome, Cell adhesion molecules, Antigen processing and presentation, Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, Intestinal immune network for IgA production, Type I diabetes mellitus, Leishmaniasis, Toxoplasmosis, Staphylococcus aureus infection, Tuberculosis, Influenza A, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Asthma, Autoimmune thyroid disease, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Viral myocarditis D04318 Glatiramer [4] 2, 13, 96, 156
239 HLA-DOB [24] Phagosome, Cell adhesion molecules, Antigen processing and presentation, Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, Intestinal immune network for IgA production, Type I diabetes mellitus, Leishmaniasis, Toxoplasmosis, Staphylococcus aureus infection, Tuberculosis, Influenza A, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Asthma, Autoimmune thyroid disease, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Viral myocarditis D04318 Glatiramer [4] 2, 13, 96, 156
240 HLA-DPA1 [24] Phagosome, Cell adhesion molecules, Antigen processing and presentation, Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, Intestinal immune network for IgA production, Type I diabetes mellitus, Leishmaniasis, Toxoplasmosis, Staphylococcus aureus infection, Tuberculosis, Influenza A, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Asthma, Autoimmune thyroid disease, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Viral myocarditis D04318 Glatiramer [4] 2, 13, 96, 156
241 HLA-DPB1 [24] Phagosome, Cell adhesion molecules, Antigen processing and presentation, Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, Intestinal immune network for IgA production, Type I diabetes mellitus, Leishmaniasis, Toxoplasmosis, Staphylococcus aureus infection, Tuberculosis, Influenza A, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Asthma, Autoimmune thyroid disease, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Viral myocarditis D04318 Glatiramer [4] 2, 13, 96, 156
242 HLA-DQA1 [24] Phagosome, Cell adhesion molecules, Antigen processing and presentation, Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, Intestinal immune network for IgA production, Type I diabetes mellitus, Leishmaniasis, Toxoplasmosis, Staphylococcus aureus infection, Tuberculosis, Influenza A, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Asthma, Autoimmune thyroid disease, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Viral myocarditis D04318 Glatiramer [4] 2, 13, 96, 156
243 HLA-DQA2 [24] Phagosome, Cell adhesion molecules, Antigen processing and presentation, Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, Intestinal immune network for IgA production, Type I diabetes mellitus, Leishmaniasis, Toxoplasmosis, Staphylococcus aureus infection, Tuberculosis, Influenza A, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Asthma, Autoimmune thyroid disease, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Viral myocarditis D04318 Glatiramer [4] 2, 13, 96, 156
244 HLA-DQB1 [24] Phagosome, Cell adhesion molecules, Antigen processing and presentation, Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, Intestinal immune network for IgA production, Type I diabetes mellitus, Leishmaniasis, Toxoplasmosis, Staphylococcus aureus infection, Tuberculosis, Influenza A, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Asthma, Autoimmune thyroid disease, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Viral myocarditis D04318 Glatiramer [4] 2, 13, 96, 156
245 HLA-DRA [24] Phagosome, Cell adhesion molecules, Antigen processing and presentation, Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, Intestinal immune network for IgA production, Type I diabetes mellitus, Leishmaniasis, Toxoplasmosis, Staphylococcus aureus infection, Tuberculosis, Influenza A, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Asthma, Autoimmune thyroid disease, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Viral myocarditis D04318 Glatiramer [4] 2, 13, 96, 156
246 HLA-DRB1 [24] Phagosome, Cell adhesion molecules, Antigen processing and presentation, Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, Intestinal immune network for IgA production, Type I diabetes mellitus, Leishmaniasis, Toxoplasmosis, Staphylococcus aureus infection, Tuberculosis, Influenza A, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Asthma, Autoimmune thyroid disease, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Viral myocarditis D04318 Glatiramer [4] 2, 13, 96, 156
247 HLA-DRB3 [24] Phagosome, Cell adhesion molecules, Antigen processing and presentation, Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, Intestinal immune network for IgA production, Type I diabetes mellitus, Leishmaniasis, Toxoplasmosis, Staphylococcus aureus infection, Tuberculosis, Influenza A, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Asthma, Autoimmune thyroid disease, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Viral myocarditis D04318 Glatiramer [4] 2, 13, 96, 156
248 HLA-DRB4 [24] Phagosome, Cell adhesion molecules, Antigen processing and presentation, Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, Intestinal immune network for IgA production, Type I diabetes mellitus, Leishmaniasis, Toxoplasmosis, Staphylococcus aureus infection, Tuberculosis, Influenza A, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Asthma, Autoimmune thyroid disease, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Viral myocarditis D04318 Glatiramer [4] 2, 13, 96, 156
249 HLA-DRB5 [24] Phagosome, Cell adhesion molecules, Antigen processing and presentation, Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, Intestinal immune network for IgA production, Type I diabetes mellitus, Leishmaniasis, Toxoplasmosis, Staphylococcus aureus infection, Tuberculosis, Influenza A, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Asthma, Autoimmune thyroid disease, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Viral myocarditis D04318 Glatiramer [4] 2, 13, 96, 156
250 HLA-E [19] Endocytosis, Phagosome, Cellular senescence, Cell adhesion molecules, Antigen processing and presentation, Natural killer cell mediated cytotoxicity, Type I diabetes mellitus, Human cytomegalovirus infection, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Viral carcinogenesis, Autoimmune thyroid disease, Allograft rejection, Graft-versus-host disease, Viral myocarditis D04318 Glatiramer [4] 2, 13, 96, 156
251 HLA-F [18] Endocytosis, Phagosome, Cellular senescence, Cell adhesion molecules, Antigen processing and presentation, Type I diabetes mellitus, Human cytomegalovirus infection, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Viral carcinogenesis, Autoimmune thyroid disease, Allograft rejection, Graft-versus-host disease, Viral myocarditis D04318 Glatiramer [4] 2, 13, 96, 156
252 HLA-G [19] Endocytosis, Phagosome, Cellular senescence, Cell adhesion molecules, Antigen processing and presentation, Natural killer cell mediated cytotoxicity, Type I diabetes mellitus, Human cytomegalovirus infection, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Viral carcinogenesis, Autoimmune thyroid disease, Allograft rejection, Graft-versus-host disease, Viral myocarditis D04318 Glatiramer [4] 2, 13, 96, 156
253 HRH1 [3] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D00454 Olanzapine [2] 2, 8
254 HRH1 [3] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D06623 Olanzapine [2] 2, 8
255 HRH2 [3] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gastric acid secretion D00295 Cimetidine [2] 2, 254
256 HRH2 [3] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gastric acid secretion D03503 Cimetidine [2] 2, 254
257 HTR2A [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels D00454 Olanzapine [2] 2, 8
258 HTR2A [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels D00820 Trazodone [1] 2
259 HTR2A [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels D06623 Olanzapine [2] 2, 8
260 HTR2A [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels D08626 Trazodone [1] 2
261 HTR2B [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels D00454 Olanzapine [2] 2, 8
262 HTR2B [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels D00820 Trazodone [1] 2
263 HTR2B [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels D06623 Olanzapine [2] 2, 8
264 HTR2B [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels D08626 Trazodone [1] 2
265 HTR2C [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels D00454 Olanzapine [2] 2, 8
266 HTR2C [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels D00820 Trazodone [1] 2
267 HTR2C [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels D06623 Olanzapine [2] 2, 8
268 HTR2C [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels D08626 Trazodone [1] 2
269 HTR6 [4] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Serotonergic synapse D00454 Olanzapine [2] 2, 8
270 HTR6 [4] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Serotonergic synapse D06623 Olanzapine [2] 2, 8
271 TUBB8 [10] Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D00570 Colchicine [7] 2, 42, 46, 56, 93, 210, 266
272 TUBB2B [10] Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D00570 Colchicine [7] 2, 42, 46, 56, 93, 210, 266
273 IL1R1 [13] MAPK signaling pathway, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Osteoclast differentiation, Hematopoietic cell lineage, Th17 cell differentiation, Inflammatory mediator regulation of TRP channels, Pathogenic Escherichia coli infection, Shigellosis, Amoebiasis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Fluid shear stress and atherosclerosis D02934 Anakinra [19] 2, 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299
274 IL2RA [11] Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, Endocytosis, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, Measles, Human T-cell leukemia virus 1 infection, Pathways in cancer D00748 Aldesleukin [6] 2, 35, 49, 65, 96, 97
275 IL2RA [11] Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, Endocytosis, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, Measles, Human T-cell leukemia virus 1 infection, Pathways in cancer D03058 Basiliximab [6] 2, 50, 66, 97, 222, 228
276 IL2RB [11] Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, Endocytosis, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Measles, Human T-cell leukemia virus 1 infection, Pathways in cancer, Transcriptional misregulation in cancer D00748 Aldesleukin [6] 2, 35, 49, 65, 96, 97
277 IL2RG [12] Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, Endocytosis, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Measles, Human T-cell leukemia virus 1 infection, Pathways in cancer, Inflammatory bowel disease, Primary immunodeficiency D00748 Aldesleukin [6] 2, 35, 49, 65, 96, 97
278 IL6R [12] EGFR tyrosine kinase inhibitor resistance, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, HIF-1 signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Th17 cell differentiation, Non-alcoholic fatty liver disease, Human cytomegalovirus infection, Coronavirus disease - COVID-19, Pathways in cancer D02596 Tocilizumab [21] 2, 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331
279 IMPDH1 [3] Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways D00752 Mycophenolate mofetil [34] 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 85, 93, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300
280 IMPDH1 [3] Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways D05094 Mycophenolate mofetil [34] 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 85, 93, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300
281 IMPDH1 [3] Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways D05095 Mycophenolate mofetil [34] 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 85, 93, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300
282 IMPDH1 [3] Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways D05096 Mycophenolic acid [36] 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 84, 85, 93, 95, 96, 162, 164, 222, 224, 226, 228, 234, 283, 284, 285, 300
283 IMPDH2 [3] Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways D00752 Mycophenolate mofetil [34] 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 85, 93, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300
284 IMPDH2 [3] Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways D05094 Mycophenolate mofetil [34] 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 85, 93, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300
285 IMPDH2 [3] Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways D05095 Mycophenolate mofetil [34] 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 85, 93, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300
286 IMPDH2 [3] Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways D05096 Mycophenolic acid [36] 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 84, 85, 93, 95, 96, 162, 164, 222, 224, 226, 228, 234, 283, 284, 285, 300
287 AR [4] Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer D00075 Testosterone [9] 1, 2, 3, 13, 60, 76, 78, 113, 265
288 AR [4] Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer D00957 Testosterone [9] 1, 2, 3, 13, 60, 76, 78, 113, 265
289 AR [4] Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer D00958 Testosterone [9] 1, 2, 3, 13, 60, 76, 78, 113, 265
290 AR [4] Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer D00959 Testosterone [9] 1, 2, 3, 13, 60, 76, 78, 113, 265
291 AR [4] Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer D03338 Calusterone [3] 2, 46, 71
292 AR [4] Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer D06085 Testosterone [9] 1, 2, 3, 13, 60, 76, 78, 113, 265
293 AR [4] Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer D06087 Testosterone [9] 1, 2, 3, 13, 60, 76, 78, 113, 265
294 KCNQ1 [6] Adrenergic signaling in cardiomyocytes, Cholinergic synapse, Gastric acid secretion, Pancreatic secretion, Protein digestion and absorption, Vibrio cholerae infection D09569 Ezogabine [2] 2, 144
295 KCNQ2 [1] Cholinergic synapse D09569 Ezogabine [2] 2, 144
296 KCNQ3 [1] Cholinergic synapse D09569 Ezogabine [2] 2, 144
297 KIT [11] MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Hematopoietic cell lineage, Melanogenesis, Pathways in cancer, Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer D10229 Masitinib [6] 2, 5, 6, 13, 46, 96
298 MAOB [14] Glycine, serine and threonine metabolism, Arginine and proline metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Alcoholism D02562 Rasagiline [7] 2, 5, 6, 13, 17, 58, 66
299 MAOB [14] Glycine, serine and threonine metabolism, Arginine and proline metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Alcoholism D08469 Rasagiline [7] 2, 5, 6, 13, 17, 58, 66
300 MAOB [14] Glycine, serine and threonine metabolism, Arginine and proline metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Alcoholism D10829 Rasagiline [7] 2, 5, 6, 13, 17, 58, 66
301 MC2R [5] cAMP signaling pathway, Neuroactive ligand-receptor interaction, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome D00146 Corticotropin [15] 2, 13, 14, 46, 49, 50, 66, 75, 78, 81, 84, 145, 193, 205, 222
302 MPO [5] Drug metabolism - other enzymes, Phagosome, Neutrophil extracellular trap formation, Transcriptional misregulation in cancer, Acute myeloid leukemia D11684 Verdiperstat [3] 2, 17, 127
303 ATP4A [4] Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D00724 Rabeprazole [2] 2, 51
304 ATP4A [4] Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D08463 Rabeprazole [2] 2, 51
305 ATP4B [4] Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D00724 Rabeprazole [2] 2, 51
306 ATP4B [4] Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D08463 Rabeprazole [2] 2, 51
307 PDE2A [6] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Olfactory transduction, Aldosterone synthesis and secretion, Morphine addiction D00528 Caffeine [9] 2, 6, 13, 21, 46, 78, 96, 97, 265
308 PDE2A [6] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Olfactory transduction, Aldosterone synthesis and secretion, Morphine addiction D01453 Caffeine [9] 2, 6, 13, 21, 46, 78, 96, 97, 265
309 PDE3A [6] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, cAMP signaling pathway, Renin secretion, Morphine addiction D00528 Caffeine [9] 2, 6, 13, 21, 46, 78, 96, 97, 265
310 PDE3A [6] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, cAMP signaling pathway, Renin secretion, Morphine addiction D01385 Ibudilast [2] 2, 13
311 PDE3A [6] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, cAMP signaling pathway, Renin secretion, Morphine addiction D01453 Caffeine [9] 2, 6, 13, 21, 46, 78, 96, 97, 265
312 PDE3A [6] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, cAMP signaling pathway, Renin secretion, Morphine addiction D04720 Levosimendan [1] 2
313 PDE3B [11] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, cAMP signaling pathway, Apelin signaling pathway, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Glucagon signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D00528 Caffeine [9] 2, 6, 13, 21, 46, 78, 96, 97, 265
314 PDE3B [11] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, cAMP signaling pathway, Apelin signaling pathway, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Glucagon signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D01385 Ibudilast [2] 2, 13
315 PDE3B [11] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, cAMP signaling pathway, Apelin signaling pathway, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Glucagon signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D01453 Caffeine [9] 2, 6, 13, 21, 46, 78, 96, 97, 265
316 PDE3B [11] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, cAMP signaling pathway, Apelin signaling pathway, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Glucagon signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D04720 Levosimendan [1] 2
317 PDE4A [5] Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D00528 Caffeine [9] 2, 6, 13, 21, 46, 78, 96, 97, 265
318 PDE4A [5] Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D01385 Ibudilast [2] 2, 13
319 PDE4A [5] Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D01453 Caffeine [9] 2, 6, 13, 21, 46, 78, 96, 97, 265
320 PDE4B [5] Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D00528 Caffeine [9] 2, 6, 13, 21, 46, 78, 96, 97, 265
321 PDE4B [5] Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D01385 Ibudilast [2] 2, 13
322 PDE4B [5] Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D01453 Caffeine [9] 2, 6, 13, 21, 46, 78, 96, 97, 265
323 PDE4C [5] Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D00528 Caffeine [9] 2, 6, 13, 21, 46, 78, 96, 97, 265
324 PDE4C [5] Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D01385 Ibudilast [2] 2, 13
325 PDE4C [5] Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D01453 Caffeine [9] 2, 6, 13, 21, 46, 78, 96, 97, 265
326 PDE4D [5] Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D00528 Caffeine [9] 2, 6, 13, 21, 46, 78, 96, 97, 265
327 PDE4D [5] Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D01385 Ibudilast [2] 2, 13
328 PDE4D [5] Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D01453 Caffeine [9] 2, 6, 13, 21, 46, 78, 96, 97, 265
329 PDE1B [7] Purine metabolism, Metabolic pathways, Calcium signaling pathway, Olfactory transduction, Taste transduction, Renin secretion, Morphine addiction D00528 Caffeine [9] 2, 6, 13, 21, 46, 78, 96, 97, 265
330 PDE1B [7] Purine metabolism, Metabolic pathways, Calcium signaling pathway, Olfactory transduction, Taste transduction, Renin secretion, Morphine addiction D01453 Caffeine [9] 2, 6, 13, 21, 46, 78, 96, 97, 265
331 PML [7] Ubiquitin mediated proteolysis, Endocytosis, Influenza A, Herpes simplex virus 1 infection, Pathways in cancer, Transcriptional misregulation in cancer, Acute myeloid leukemia D00094 Tretinoin [6] 2, 62, 63, 75, 94, 231
332 PPARG [11] PPAR signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Osteoclast differentiation, Thermogenesis, Non-alcoholic fatty liver disease, Huntington disease, Pathways in cancer, Transcriptional misregulation in cancer, Thyroid cancer, Lipid and atherosclerosis D00945 Pioglitazone [17] 2, 6, 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299
333 PPARG [11] PPAR signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Osteoclast differentiation, Thermogenesis, Non-alcoholic fatty liver disease, Huntington disease, Pathways in cancer, Transcriptional misregulation in cancer, Thyroid cancer, Lipid and atherosclerosis D08378 Pioglitazone [17] 2, 6, 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299
334 PPP3CA [33] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00107 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
335 PPP3CA [33] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D08556 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
336 PPP3CB [33] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00107 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
337 PPP3CB [33] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D08556 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
338 PPP3CC [33] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00107 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
339 PPP3CC [33] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D08556 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
340 PPP3R1 [32] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00107 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
341 PPP3R1 [32] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D08556 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
342 PPP3R2 [32] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00107 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
343 PPP3R2 [32] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D08556 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
344 PRKAA1 [20] FoxO signaling pathway, Autophagy - animal, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Apelin signaling pathway, Tight junction, Circadian rhythm, Thermogenesis, Insulin signaling pathway, Adipocytokine signaling pathway, Oxytocin signaling pathway, Glucagon signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Alcoholic liver disease, Hypertrophic cardiomyopathy, Fluid shear stress and atherosclerosis D00944 Metformin [24] 2, 6, 8, 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 225, 233, 265, 285, 299, 301
345 PRKAA1 [20] FoxO signaling pathway, Autophagy - animal, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Apelin signaling pathway, Tight junction, Circadian rhythm, Thermogenesis, Insulin signaling pathway, Adipocytokine signaling pathway, Oxytocin signaling pathway, Glucagon signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Alcoholic liver disease, Hypertrophic cardiomyopathy, Fluid shear stress and atherosclerosis D04966 Metformin [24] 2, 6, 8, 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 225, 233, 265, 285, 299, 301
346 PRKAA2 [20] FoxO signaling pathway, Autophagy - animal, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Apelin signaling pathway, Tight junction, Circadian rhythm, Thermogenesis, Insulin signaling pathway, Adipocytokine signaling pathway, Oxytocin signaling pathway, Glucagon signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Alcoholic liver disease, Hypertrophic cardiomyopathy, Fluid shear stress and atherosclerosis D00944 Metformin [24] 2, 6, 8, 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 225, 233, 265, 285, 299, 301
347 PRKAA2 [20] FoxO signaling pathway, Autophagy - animal, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Apelin signaling pathway, Tight junction, Circadian rhythm, Thermogenesis, Insulin signaling pathway, Adipocytokine signaling pathway, Oxytocin signaling pathway, Glucagon signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Alcoholic liver disease, Hypertrophic cardiomyopathy, Fluid shear stress and atherosclerosis D04966 Metformin [24] 2, 6, 8, 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 225, 233, 265, 285, 299, 301
348 GABRQ [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
349 GABRQ [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00696 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
350 GABRQ [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D05028 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
351 MAP2K1 [89] EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Chemokine signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, Oocyte meiosis, Autophagy - animal, mTOR signaling pathway, PI3K-Akt signaling pathway, Apoptosis, Cellular senescence, Vascular smooth muscle contraction, VEGF signaling pathway, Apelin signaling pathway, Osteoclast differentiation, Focal adhesion, Gap junction, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, B cell receptor signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, TNF signaling pathway, Long-term potentiation, Neurotrophin signaling pathway, Cholinergic synapse, Serotonergic synapse, Long-term depression, Regulation of actin cytoskeleton, Insulin signaling pathway, GnRH signaling pathway, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Alcoholism, Salmonella infection, Yersinia infection, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Chemical carcinogenesis - reactive oxygen species, Colorectal cancer, Renal cell carcinoma, Pancreatic cancer, Endometrial cancer, Glioma, Prostate cancer, Thyroid cancer, Melanoma, Bladder cancer, Chronic myeloid leukemia, Acute myeloid leukemia, Non-small cell lung cancer, Breast cancer, Hepatocellular carcinoma, Gastric cancer, Central carbon metabolism in cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D10175 Trametinib [4] 2, 34, 279, 280
352 MAP2K2 [77] EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, Autophagy - animal, mTOR signaling pathway, PI3K-Akt signaling pathway, Apoptosis, Cellular senescence, Vascular smooth muscle contraction, VEGF signaling pathway, Apelin signaling pathway, Gap junction, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, B cell receptor signaling pathway, Fc epsilon RI signaling pathway, Long-term potentiation, Neurotrophin signaling pathway, Long-term depression, Regulation of actin cytoskeleton, Insulin signaling pathway, GnRH signaling pathway, Estrogen signaling pathway, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Chemical carcinogenesis - reactive oxygen species, Colorectal cancer, Renal cell carcinoma, Endometrial cancer, Glioma, Prostate cancer, Thyroid cancer, Melanoma, Bladder cancer, Chronic myeloid leukemia, Acute myeloid leukemia, Non-small cell lung cancer, Breast cancer, Hepatocellular carcinoma, Gastric cancer, Central carbon metabolism in cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D10175 Trametinib [4] 2, 34, 279, 280
353 KCNQ5 [1] Cholinergic synapse D09569 Ezogabine [2] 2, 144
354 RTN4 [1] Alzheimer disease D10331 Ozanezumab [1] 2
355 PTGIR [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Platelet activation D01385 Ibudilast [2] 2, 13
356 PTGS2 [22] Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D00567 Celecoxib [10] 2, 3, 34, 46, 70, 89, 107, 161, 171, 271
357 RARA [5] Th17 cell differentiation, Estrogen signaling pathway, Pathways in cancer, Transcriptional misregulation in cancer, Acute myeloid leukemia D00094 Tretinoin [6] 2, 62, 63, 75, 94, 231
358 RARB [4] Pathways in cancer, Small cell lung cancer, Non-small cell lung cancer, Gastric cancer D00094 Tretinoin [6] 2, 62, 63, 75, 94, 231
359 ROCK1 [20] cGMP-PKG signaling pathway, cAMP signaling pathway, Chemokine signaling pathway, Sphingolipid signaling pathway, Vascular smooth muscle contraction, TGF-beta signaling pathway, Axon guidance, Focal adhesion, Tight junction, Platelet activation, Leukocyte transendothelial migration, Regulation of actin cytoskeleton, Oxytocin signaling pathway, Pathogenic Escherichia coli infection, Shigellosis, Yersinia infection, Human cytomegalovirus infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer D07941 Fasudil [4] 2, 5, 7, 51
360 SCN1A [1] Dopaminergic synapse D00639 Mexiletine [4] 2, 10, 113, 114
361 SCN1A [1] Dopaminergic synapse D00642 Quinidine [3] 2, 8, 13
362 SCN1A [1] Dopaminergic synapse D00643 Quinidine [3] 2, 8, 13
363 SCN1A [1] Dopaminergic synapse D02272 Quinidine [3] 2, 8, 13
364 SCN1A [1] Dopaminergic synapse D08215 Mexiletine [4] 2, 10, 113, 114
365 SCN1A [1] Dopaminergic synapse D08458 Quinidine [3] 2, 8, 13
366 SCN2A [1] Taste transduction D00639 Mexiletine [4] 2, 10, 113, 114
367 SCN2A [1] Taste transduction D00642 Quinidine [3] 2, 8, 13
368 SCN2A [1] Taste transduction D00643 Quinidine [3] 2, 8, 13
369 SCN2A [1] Taste transduction D02272 Quinidine [3] 2, 8, 13
370 SCN2A [1] Taste transduction D08215 Mexiletine [4] 2, 10, 113, 114
371 SCN2A [1] Taste transduction D08458 Quinidine [3] 2, 8, 13
372 SCN3A [1] Taste transduction D00639 Mexiletine [4] 2, 10, 113, 114
373 SCN3A [1] Taste transduction D00642 Quinidine [3] 2, 8, 13
374 SCN3A [1] Taste transduction D00643 Quinidine [3] 2, 8, 13
375 SCN3A [1] Taste transduction D02272 Quinidine [3] 2, 8, 13
376 SCN3A [1] Taste transduction D07299 Lacosamide [3] 2, 46, 149
377 SCN3A [1] Taste transduction D08215 Mexiletine [4] 2, 10, 113, 114
378 SCN3A [1] Taste transduction D08458 Quinidine [3] 2, 8, 13
379 SCN5A [1] Adrenergic signaling in cardiomyocytes D00639 Mexiletine [4] 2, 10, 113, 114
380 SCN5A [1] Adrenergic signaling in cardiomyocytes D00642 Quinidine [3] 2, 8, 13
381 SCN5A [1] Adrenergic signaling in cardiomyocytes D00643 Quinidine [3] 2, 8, 13
382 SCN5A [1] Adrenergic signaling in cardiomyocytes D02272 Quinidine [3] 2, 8, 13
383 SCN5A [1] Adrenergic signaling in cardiomyocytes D08215 Mexiletine [4] 2, 10, 113, 114
384 SCN5A [1] Adrenergic signaling in cardiomyocytes D08458 Quinidine [3] 2, 8, 13
385 SCN9A [1] Taste transduction D00639 Mexiletine [4] 2, 10, 113, 114
386 SCN9A [1] Taste transduction D00642 Quinidine [3] 2, 8, 13
387 SCN9A [1] Taste transduction D00643 Quinidine [3] 2, 8, 13
388 SCN9A [1] Taste transduction D02272 Quinidine [3] 2, 8, 13
389 SCN9A [1] Taste transduction D07299 Lacosamide [3] 2, 46, 149
390 SCN9A [1] Taste transduction D08215 Mexiletine [4] 2, 10, 113, 114
391 SCN9A [1] Taste transduction D08458 Quinidine [3] 2, 8, 13
392 SLC6A4 [2] Synaptic vesicle cycle, Serotonergic synapse D00820 Trazodone [1] 2
393 SLC6A4 [2] Synaptic vesicle cycle, Serotonergic synapse D02567 Escitalopram [3] 2, 6, 13
394 SLC6A4 [2] Synaptic vesicle cycle, Serotonergic synapse D07704 Escitalopram [3] 2, 6, 13
395 SLC6A4 [2] Synaptic vesicle cycle, Serotonergic synapse D07913 Escitalopram [3] 2, 6, 13
396 SLC6A4 [2] Synaptic vesicle cycle, Serotonergic synapse D08626 Trazodone [1] 2
397 SNAP25 [2] Synaptic vesicle cycle, Insulin secretion D00783 Botulinum toxin type A [13] 2, 5, 6, 7, 13, 15, 17, 36, 51, 70, 113, 149, 226
398 SNAP25 [2] Synaptic vesicle cycle, Insulin secretion D02735 Botulinum toxin type B [4] 2, 6, 13, 51
399 SOD1 [8] Peroxisome, Longevity regulating pathway - multiple species, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - reactive oxygen species D11811 Tofersen [1] 2
400 SRC [42] EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Rap1 signaling pathway, Chemokine signaling pathway, Mitophagy - animal, Endocytosis, Axon guidance, VEGF signaling pathway, Focal adhesion, Adherens junction, Tight junction, Gap junction, Platelet activation, Neutrophil extracellular trap formation, C-type lectin receptor signaling pathway, GABAergic synapse, Inflammatory mediator regulation of TRP channels, Regulation of actin cytoskeleton, GnRH signaling pathway, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Bacterial invasion of epithelial cells, Epithelial cell signaling in Helicobacter pylori infection, Pathogenic Escherichia coli infection, Shigellosis, Yersinia infection, Tuberculosis, Hepatitis B, Human cytomegalovirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Viral carcinogenesis, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Chemical carcinogenesis - reactive oxygen species, Bladder cancer, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D03252 Bosutinib [2] 2, 67
401 SRD5A1 [2] Steroid hormone biosynthesis, Metabolic pathways D03820 Dutasteride [2] 1, 2
402 SRD5A2 [3] Steroid hormone biosynthesis, Metabolic pathways, Prostate cancer D03820 Dutasteride [2] 1, 2
403 TNF [67] Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Apoptosis, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Asthma, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D00754 Thalidomide [20] 2, 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331
404 TNNC2 [1] Calcium signaling pathway D11363 Reldesemtiv [2] 2, 3
405 C3 [17] Neuroactive ligand-receptor interaction, Phagosome, Complement and coagulation cascades, Neutrophil extracellular trap formation, Alcoholic liver disease, Shigellosis, Pertussis, Legionellosis, Leishmaniasis, Chagas disease, Staphylococcus aureus infection, Tuberculosis, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Coronavirus disease - COVID-19, Viral carcinogenesis, Systemic lupus erythematosus D11613 Pegcetacoplan [3] 2, 62, 222
406 C5 [10] Neuroactive ligand-receptor interaction, Complement and coagulation cascades, Neutrophil extracellular trap formation, Alcoholic liver disease, Prion disease, Pertussis, Staphylococcus aureus infection, Herpes simplex virus 1 infection, Coronavirus disease - COVID-19, Systemic lupus erythematosus D11054 Ravulizumab [7] 2, 11, 13, 50, 62, 66, 109
407 TUBB2A [10] Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D00570 Colchicine [7] 2, 42, 46, 56, 93, 210, 266
408 TRPV1 [2] Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D00250 Capsaicin [5] 2, 6, 19, 86, 226
409 XDH [5] Purine metabolism, Caffeine metabolism, Drug metabolism - other enzymes, Metabolic pathways, Peroxisome D01206 Febuxostat [3] 2, 6, 13
410 IL1R2 [7] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Amoebiasis, Human T-cell leukemia virus 1 infection, Transcriptional misregulation in cancer, Prostate cancer, Fluid shear stress and atherosclerosis D02934 Anakinra [19] 2, 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299
411 ALDH5A1 [3] Alanine, aspartate and glutamate metabolism, Butanoate metabolism, Metabolic pathways D00399 Valproic acid [17] 2, 3, 5, 6, 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331
412 TUBB1 [10] Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D00570 Colchicine [7] 2, 42, 46, 56, 93, 210, 266
413 TUBB6 [10] Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D00570 Colchicine [7] 2, 42, 46, 56, 93, 210, 266
414 PDE5A [3] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway D00528 Caffeine [9] 2, 6, 13, 21, 46, 78, 96, 97, 265
415 PDE5A [3] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway D01453 Caffeine [9] 2, 6, 13, 21, 46, 78, 96, 97, 265
416 CACNA1I [7] MAPK signaling pathway, Calcium signaling pathway, Circadian entrainment, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome D00399 Valproic acid [17] 2, 3, 5, 6, 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331
417 CACNA1H [7] MAPK signaling pathway, Calcium signaling pathway, Circadian entrainment, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome D00399 Valproic acid [17] 2, 3, 5, 6, 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331
418 CACNA1G [8] MAPK signaling pathway, Calcium signaling pathway, Circadian entrainment, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome D00399 Valproic acid [17] 2, 3, 5, 6, 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331
419 KCNQ4 [1] Cholinergic synapse D09569 Ezogabine [2] 2, 144
420 ROCK2 [21] cGMP-PKG signaling pathway, cAMP signaling pathway, Chemokine signaling pathway, Sphingolipid signaling pathway, Vascular smooth muscle contraction, Wnt signaling pathway, Axon guidance, Focal adhesion, Tight junction, Platelet activation, Leukocyte transendothelial migration, Regulation of actin cytoskeleton, Oxytocin signaling pathway, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Yersinia infection, Human cytomegalovirus infection, Pathways in cancer, Proteoglycans in cancer, Lipid and atherosclerosis D07941 Fasudil [4] 2, 5, 7, 51
421 GABBR2 [7] cAMP signaling pathway, Neuroactive ligand-receptor interaction, GABAergic synapse, Taste transduction, Estrogen signaling pathway, GnRH secretion, Morphine addiction D00241 Baclofen [7] 2, 10, 13, 18, 65, 149, 206
422 SV2A [1] ECM-receptor interaction D00709 Levetiracetam [5] 2, 4, 6, 13, 307